BillionToOne is trading at $98.37, down 4.24%, with biotech-sector weakness the clearest available context.
- No new company-specific announcement explaining the October 16 decline surfaced; the latest company release set the Q3 results date for November 4.
- Biotech ETF XBI was down 2.06%, consistent with pressure on biotech shares; broader indices were mixed.
- The October 7 Northstar Response study predates this move and does not establish a cause.